-

Agilent Automated Workflows at SLAS2025: Connecting with Confidence

Building the lab of the future today by enhancing lab productivity with robust and reliable automation technology

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) announced today that it will feature new automated laboratory workflow solutions at the SLAS2025 International Conference & Exhibition being held January 25-29, at the San Diego Convention Center in California. Agilent is a leader in advancing automation solutions to help customers optimize lab performance, efficiency, and reproducibility across their entire pipeline, from research and drug discovery to development and manufacturing processes.

Automation is becoming increasingly critical for labs as they navigate the competitive landscape. Agilent's automation solutions include sample and standard preparation, auto dilution, sample delivery, and washout. These solutions cover cell analysis, genomics, proteomics, biomolecule analysis, and mass spectrometry in regulated and non-regulated labs. By automating these tasks, scientists and lab technicians can focus on more important work. Automated sample preparation becomes more manageable, accurate, and consistent, which increases data quality and reduces the time needed to get results, ultimately leading to better decisions.

“Connecting automated solutions to your workflows allows for current manual processes to be a thing of the past, significantly boosting lab productivity, making lab managers’ days easier and giving back time to focus on other tasks,” stated Lars Kristiansen, general manager of Agilent’s Automation Solutions Business. “SLAS is the perfect platform for us to showcase how our cutting-edge automation solutions push the boundaries of what's possible. We're dedicated to delivering innovative workflow solutions that advance automation and drive customer success.”

SLAS attendees are invited to visit exhibit booth #1529 to discover how Agilent's automation solutions can confidently connect and enhance their labs. Highlighted innovations will include:

  • NovoCyte Opteon Spectral Flow Cytometer ‒ The NovoCyte Opteon boasts up to 5 lasers and 73 detectors, a proprietary optics design, and advanced electronics, enabling it to deliver data with high resolution and sensitivity.
  • SureSelect Cancer CGP Assay ‒ The SureSelect Cancer CGP Assay offers comprehensive genomic profiling for solid tumors, detecting various somatic variants and immuno-oncology biomarkers.
  • ePrep Partnership ‒ Agilent has partnered with ePrep to offer streamlined end-to-end workflow solutions for GC/MS and LC/MS analyses.
  • Avida ‒ Agilent Avida offers high-performance target enrichment for DNA sequencing, optimized for sensitive variant detection and streamlined workflows.

A Solutions Spotlight Presentation “Revolutionizing Viral Infectivity Assays: High-Resolution Automated Cell Imaging Meets AI/ML Analysis” will be held Monday, January 27, from 11:30 AM - 11:50 AM PT in the SLAS Solutions Spotlight Theater (Booth #2907) highlighting the Agilent BioTek Cytation platform. Presenters include Ilya Goldberg, Ph.D., Chief Scientific Officer at ViQi, and Joe Clayton, Ph.D., Director of Application Development and Technical Marketing, in the Cell Analysis Division at Agilent.

Additionally Agilent will participate in a roundtable discussion entitled “Robotic automation is the gateway to the Lab of the Future,” hosted by ABB Robotics. The conversation will highlight how robots can unlock new possibilities in the lab, and explore some of the challenges that can be solved using robots. The roundtable will be held on Tuesday, January 28, from 8:30 AM - 10:00 AM PT in Room #26A at the conference venue, and is open to all SLAS attendees.

Agilent is a proud Diamond Sponsor of the SLAS2025 International Conference & Exhibition, highlighting Agilent's commitment to advancing laboratory automation and life sciences discovery.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.51 billion in fiscal year 2024 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

Contacts

Media Contact
Naomi Goumillout
Agilent Technologies
+1.978.314.1862
naomi.goumillout@agilent.com

AGILENT TECHNOLOGIES INC

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Versions

Contacts

Media Contact
Naomi Goumillout
Agilent Technologies
+1.978.314.1862
naomi.goumillout@agilent.com

More News From AGILENT TECHNOLOGIES INC

Agilent Showcases Solutions and Partnerships Transforming Cancer Research and Therapeutics at AACR 2025

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) announced today its participation at the American Association for Cancer Research (AACR) Annual Meeting on April 25-30, 2025 in Chicago, Illinois. Innovative Agilent products and partnerships playing a crucial role in transforming cancer research, diagnostics, and therapeutics will be featured, including: Agilent Avida DNA Cancer Panels – Based on cutting-edge next-generation sequencing (NGS) target enrichment solutions t...

Agilent Receives European IVDR Certification for Companion Diagnostic Assay in Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 22C3 pharmDx (Code SK006) assay has received European IVDR certification for the use as a Companion Diagnostic (CDx) to aid in the identification of gastric or gastroesophageal Junction (GEJ) adenocarcinoma patients who may be eligible for treatment with KEYTRUDA® (pembrolizumab)1. PD-L1 IHC 22C3 pharmDx (Code SK006) is approved for exclusive use with the Agilent Autostainer Link 48 advanced...

Agilent to Announce Second-Quarter Fiscal Year 2025 Financial Results on May 28

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) will release financial results for the second quarter of fiscal year 2025 after the stock market closes on Wednesday, May 28. In addition, the company will host a conference call to discuss the results at 1:30 p.m. PDT on the same day. To join the listen-only conference call webcast, click the link on the Events section of Agilent’s investor relations website. A recording of the call also will be available on the website...
Back to Newsroom